Cinclus Pharma publishes its Annual Report for 2024

REG

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company developing molecules for the treatment of gastric acid-related diseases, today announced that its Annual Report for 2024 has been published.

The Annual Report is available at https://cincluspharma.com/investors/financial-reports/. The Swedish version of the report is also available in European Single Electronic Format (ESEF).

“The trend is clear. In many of the countries and regions where first-generation PCABs are launched, these are gradually taking over the market from the old proton pump inhibitors (PPIs). Our ambition is to develop a unique next-generation PCAB that meets the medical need and provides the conditions to do exactly what AstraZeneca did when they launched the next-generation PPI, Nexium, twelve years after the introduction of Losec, i.e. to take over the market”, says Christer Ahlberg, CEO, Cinclus Pharma.
 

Datum 2025-04-17, kl 14:00
Källa MFN
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.